Investigating how chemotherapy affects ovarian function and fertility in young women
Official title: Oogenic JNK in gonadotoxic chemotherapy-induced primary ovarian insufficiency
Funded at Rutgers Biomedical and Health Sciences · NIH-11170518 · Data updated 2026-11-12
This study is looking at how common chemotherapy drugs can affect the ovaries and fertility in young women who have survived cancer, with the hope of finding ways to protect their reproductive health during treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project start | August 16, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $629,384 |
| NIH project number | 5R01HD115810-02 |
| Project ID | NIH-11170518 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are young female cancer patients who are at risk of developing ovarian insufficiency due to chemotherapy.
✕Less likely to help
Patients who are not undergoing chemotherapy or who are not female may not receive any benefit from this research.
What this research studies
This research focuses on understanding the impact of common chemotherapy drugs on ovarian function, specifically how they can lead to primary ovarian insufficiency (POI) and infertility in young female cancer survivors. The study examines the mechanisms by which these drugs cause damage to the oocytes in primordial follicles, which are crucial for female fertility. By using genetically modified mouse models, the researchers aim to identify specific signaling pathways involved in this process, potentially leading to new strategies to protect ovarian function during cancer treatment.
Why it matters
Potential benefit: If successful, this research could lead to improved fertility preservation strategies for young women undergoing chemotherapy.
How similar studies have gone: Previous research has shown that understanding the mechanisms of chemotherapy-induced ovarian damage can lead to protective strategies, indicating that this approach has potential for success.
Where this research is happening
-
Rutgers Biomedical and Health Sciences
Newark, United States Active
Researchers
- Principal investigator: Xiao, Shuo — Rutgers Biomedical and Health Sciences
- Study coordinator: Xiao, Shuo
Related research
Other NIH-funded projects on the same topics.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Dual targeting of heart cell receptors to prevent chemotherapy heart damage
Atrial patients receiving the chemotherapy drug doxorubicin may be protected from heart damage by targeting two heart cell receptors at once.
-
A 3D ultrasound scanner to see early chemotherapy response in breast cancer
A new 3D ultrasound imaging method will be tested to see if it can quickly show whether breast cancer is responding to chemotherapy.
-
Non-invasive, microscopic biomarkers to detect CIPN in chemotherapy patients
This grant aims to develop a non-invasive imaging method to measure nerve changes in patients undergoing chemotherapy to better understand and monitor chemotherapy-induced peripheral neuropathy (CIPN).
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
-
Genetic clues for doxorubicin heart risk using patient-derived heart cells
A research project tests how human heart cells grown from stem cells react to a common chemotherapy to see which genetic differences may raise the risk of heart damage.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.